Magnevist

   
Google
 
Web NewDrugInformation.com

Magnevist


Drug - Magnevist
The trade name of the product as shown on the labeling.

Dosage - INJECTABLE; INJECTION
The product dosage form and route separated by a semi-colon.

Active Ingredient(s) - Gadopentetate Dimeglumine
Multiple ingredients are in alphabetical order.

Strength - 469.01MG/ML
The potency of the active ingredient(s), Gadopentetate Dimeglumine. May repeat for multiple part products.

Applicant - BERLEX
The firm name holding legal responsibility for Magnevist. The firm name is condensed to a maximum twenty character unique string.

New Drug Application (NDA) Number - 021037
The FDA assigned number to Magnevist. Format is nnnnnn.

Product Number - 001
The FDA assigned number to identify Magnevist. Each strength is a separate product. May repeat for multiple part products. Format is nnn.

Therapeutic Equivalence (TE) Code -
The TE Code indicates the therapeutic equivalence rating of generic to innovator Rx products.

Approval Date - Mar 10, 2000
The date Magnevist was approved as stated in the FDA approval letter to the applicant. The format is Mmm dd, yyyy. Products approved prior to the January 1, 1982 contain the phrase: "Approved prior to Jan 1, 1982".

Reference Listed Drug (RLD) - Yes
The pioneer or innovator of Magnevist. The RLD identifies the product Abbreviated New Drug Applications (ANDA) use as a reference. Format is Yes or No.

Type - RX
The group or category of approved drugs Magnevist is in. Format is RX, OTC, DISCN.

Applicant Full Name - Berlex Inc
The full name of the firm holding legal responsibility for the new application of Magnevist.

Magnevist